Neuronal and Glial Biomarkers in Stroke

Completed

Conditions studied: Stroke

In brief

The purpose of this research study is to determine if there are molecules in the blood that indicate when a person has had a stroke, and what type of stroke they have had, so that appropriate treatment may be begun as soon as possible. This study is also being conducted to determine whether these molecules can help to predict long-term health following stroke. Some of these potential molecules, also called biomarkers, include Neuronal biomarker ubiquitin C-terminal hydrolase-L1 (UCH-L1), Glial markers such as glial fibrillary acidic protein (GFAP), and a neuroprotective enzyme called angiotensin converting enzyme 2 (ACE2), which has activity that has been shown to be helpful cardiovascular disease and shown to be altered in animal models of acute stroke, where it is also shown to provide neuronal protection.

Key facts

Study ID

NCT02409043

Run by

University of Florida

People needed

99

Starts

2014-07-01

Expected to finish

2015-12-01

Last updated by the study team

2017-09-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Stroke, ischemic or hemorrhagic, is confirmed by clinical and/or imaging evidence
• For control participants, no acute or recent stroke

You may not qualify if…

• Onset of stroke symptoms cannot be confirmed to be less than 18 hours

Where it is running

• University of Florida — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.